Search research articles
Contact Us
Filters
Showing results (61-70 of 80) with videos related to
Page
of 8
Sort By:
The Oncologist
|
May 30, 2024
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
Julia L Glade Bender, Kerice Pinkney, Paul M Williams, et al.
Journal of the National Cancer Institute
|
May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
Susan N Chi, Joanna S Yi, P Mickey Williams, et al.
JCO Precision Oncology
|
August 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P
Filip Janku, Opeyemi A Jegede, Shannon L Puhalla, et al.
The Oncologist
|
June 14, 2024
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G
Marie V Nelson, AeRang Kim, P Mickey Williams, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2
Jun Gong, Alain C Mita, Zihan Wei, et al.
JCO Precision Oncology
|
April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E
Monica F Chen, Zihe Song, Helena A Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Roisin M Connolly, Victoria Wang, David M Hyman, et al.
JCO Precision Oncology
|
December 18, 2024
Phase II Study of Defactinib (VS6063) in Patients With Tumors With <i>NF2</i> Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Jun Gong, Alain C Mita, Zihan Wei, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 80) with videos related to
Sort By:
Page
of 8
The Oncologist
|
May 30, 2024
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
Julia L Glade Bender, Kerice Pinkney, Paul M Williams, et al.
Journal of the National Cancer Institute
|
May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
Susan N Chi, Joanna S Yi, P Mickey Williams, et al.
JCO Precision Oncology
|
August 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P
Filip Janku, Opeyemi A Jegede, Shannon L Puhalla, et al.
The Oncologist
|
June 14, 2024
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G
Marie V Nelson, AeRang Kim, P Mickey Williams, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2
Jun Gong, Alain C Mita, Zihan Wei, et al.
JCO Precision Oncology
|
April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E
Monica F Chen, Zihe Song, Helena A Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Roisin M Connolly, Victoria Wang, David M Hyman, et al.
JCO Precision Oncology
|
December 18, 2024
Phase II Study of Defactinib (VS6063) in Patients With Tumors With <i>NF2</i> Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Jun Gong, Alain C Mita, Zihan Wei, et al.
Page
of 8